In critically ill patients with COVID-19, antiplatelet therapy did not increase organ support-free days at 21 d.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35785539.
- Also identified by DOI 10.7326/J22-0046.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
REMAP-CAP Writing Committee for the REMAP-CAP Investigators. <b>Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial.</b> JAMA. 2022;327:1247-59. 35315874.
Medical subject headings
- COVID-19